123
region. The recently developed incident dark-field illumination-
based CytoCam microscope syste
m 1 is able to measure the oral
microcirculation at the patient chairside.
Objectives:
The aim of this study was to determine the clin-
ical feasibility of examining and measuring
in vivo
late oral
microcirculatory irradiation injury with the CytoCam handheld
microscope.
Methods:
In a case-control observational study images were
obtained bilaterally from the mandibular gingiva and buccal
mucosa in 14 HN cancer patients and 14 healthy age-matched con-
trols. Tissue functional capillary density (FCD), vessel diameter
(Øbv), and microvascular flow index (MFI) were analysed.
Findings:
Mean gingival and buccal FCD in healthy controls
was 66
±
23 cpll/mm
2
and 19
±
6 cpll/mm
2
, respectively. Buccal
mucosa mean Øbv in healthy controls was 15
±
2 m. A statisti-
cally significant decrease in mean FCD in irradiated mandibular
gingiva was found (
P
< 0.001) and an increased mean Øbv in
irradiated buccal mucosa (
P
< 0.05). No significant differences in
mean buccal FCD was found and MFI was equal in both groups.
Conclusion:
Noninvasive measurements of the oral microcir-
culation using CytoCam microscopy was feasible for detecting
pathophysiological alterations in capillary density and vessel
diameters between irradiated and healthy tissues.
Reference
Hutchings, S., Watts, S., & Kirkman, E. (2016). The Cytocam video micro-
scope. A new method for visualising the microcirculation using Incident
Dark Field technology.
Clin Hemorheol Microcirc
,
62
, 261–271.
http://dx.doi.org/10.1016/j.ijom.2017.02.429Major maxillofacial surgery in the over 80-year-old patient
— a review of outcomes for East Kent 1997–2016
A. Hills
∗
, J. Patel, H. Dent, J. Mckenzie, N. Goodger,
C. Hendy
East Kent Hospitals University NHS Foundation Trust, United
Kingdom
Background:
Elderly patients are generally frailer and carry a
higher comorbidity burden than the general population, therefore
major surgery holds significant risk of morbidity and mortality for
them.
Objectives:
Review outcomes of major maxillofacial surgeries in
the over 80s.
Methods:
The electronic theatre database (Theatreman) was used
to identify all maxillofacial surgery procedures in patients over 80
years old with duration of surgery greater than 4 h between 1997
and 2016. Intensive care length of stay (LOS), hospital LOS, and
date of death if known were established using our clinical database
(iSOFT PAS) cross-referenced against care records. Median sur-
vival calculated using Kaplan–Meier.
Results:
107 patients were identified (60 male, 47 female) with a
median age of 84 years (range, 80–94 years). 94 had malignant,
and 13 locally invasive disease. All underwent local resection.
82 had neck dissections, 11 had free flaps, and 18 had local flap
reconstruction. No flaps failed. The malignant cases median oper-
ation duration was 421 min (250–1170 min) compared to local
disease cases 296 min (244–383 min). Malignant disease median
ITU LOS was 1 day, five died in hospital, four within 30 days of
surgery and one within 24 h. Their median hospital LOS was 11
days (1–132 days) and median survival 17 months. Local disease
median survival was 63 months. None required ITU, median hos-
pital LOS was 3 days (1–34), and none died in hospital or within
30 days.
Conclusion:
30 day and in hospital mortality is low and confined
to malignant disease. Long-term survival is markedly impaired in
malignant disease.
http://dx.doi.org/10.1016/j.ijom.2017.02.430125
I brachytherapy alone for recurrent or locally advanced
salivary gland cancers of maxillary region
M.W. Huang
∗
, L. Zheng, Y. Shi, S.M. Liu, J. Zhang,
J.G. Zhang
Department of Oral and Maxillofacial Surgery, Peking
University School and Hospital of Stomatology, Beijing, China
Background:
It is still a problem to treat unresectable recurrent
or locally advanced salivary gland cancers of maxillary region,
which had a low five-year local control of 35–46%.
Objectives:
To present our treatment experiences and results, and
to evaluate the feasibility and effectiveness of
125
I brachyther-
apy in recurrent and/or locally advanced salivary gland cancers of
maxillary region.
Methods:
36 patients with recurrent and/or locally advanced sali-
vary gland cancers of maxillary region completed
125
I implant
brachytherapy in Stomatology School and Hospital of Peking Uni-
versity from 2010 to 2015. Eighteen cases were recurrent cases
after prior surgeries and radiation. And other 18 cases were pri-
mary tumours. All patients received interstitial
125
I seeds implant
alone under the three-dimensional individual template guide. The
prescribed dose was 120–160 Gy. The activity of
125
I seeds were
18.5–33.3MBq per seed. The number of seeds implanted was
16–125 (median, 55).
Findings and Conclusion:
Followed 6–65 months (median, 38
months), the two-year and five-year local control rates were
86.5% and 60.2%, respectively. The two-year and five-year over-
all survival rates were 93.8% and 66.2%. Tumours >6 cm had
significantly lower local control and survival rates. No severe
complications (Radiation Therapy Oncology Group, 3–4) were
observed during the follow-up.
125
I brachytherapy was an elec-
tive alternative to treat local advanced unresectable or recurrent
salivary gland cancers of maxillary region with few complications.
http://dx.doi.org/10.1016/j.ijom.2017.02.431Evidence on role of chemotherapy in head neck osteosarcoma
T. Ji
∗
, Y.M. Chen, S. Gokavarapu, W. Cao
Department of Oral Maxillofacial – Head Neck Oncology, Ninth
People’s Hospital, School of Medicine, Shanghai Jiao Tong
University, Shanghai, China
Background:
Osteosarcoma is an aggressive bone malignancy
rarely presenting in head and neck sites, the trials for extrem-
ity osteosarcoma show improved survival by chemotherapy. The
head and neck osteosarcomas (HNOs) were excluded in these tri-
als because of atypical presentation and disease course. Further,
sufficient numbers were not possible for a trial.
Objectives:
We present a largest retrospective study from single
institute investigating the role of chemotherapy in the management
of HNOs.




